Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, has announced that following the site’s twentieth commercial product approval, it is investing nearly $14 million to expand biologics packaging capabilities and capacity at its Bloomington, Indiana, biologics manufacturing facility. Construction of the 15,000-square-foot facility…
Catalent Expands Clinical Packaging Capabilities in Shanghai
Catalent to Open Second Clinical Supply Facility in China
Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, plans to invest $2.5 million in a new, second clinical supply facility in Shanghai, China, due to open in early 2019. When completed, the facility is expected to employ 100 people and will double Catalent’s total clinical…
Catalent Names Brearley To Key Role At Wisconsin Biomanufacturing Facility
Catalent Pharma Solutions, a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, today announced that Graham Brearley, Ph.D., has been appointed as general manager of the company’s Madison, WI facility. He will report to Brian Riley, vice president of operations, biologics, and specialty drug delivery. In his most…
Study Of Biological Medication For Methamphetamine Users Getting Underway
Phamaceutical company InterveXion has enrolled the first patient in STAMPOUT, the first trial in methamphetamine users of the anti-methamphetamine antibody IXT-m200. STAMPOUT will be a phase 2a, parallel-group, placebo-controlled, double-blind study of the effect of IXT-m200 on methamphetamine pharmacokinetics and subjective effects in methamphetamine users. Catalent Pharma Solutions supported the InterveXion effort by engineering the cell…
Catalent And Valerius To Collaborate On Manufacture Of Specialty Biosimilars
Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, and Valerius Biopharma AG, a Swiss biopharmaceutical company providing interchangeable treatment options for high-priced orphan and non-orphan biologics, plan to collaborate on the development and manufacture of Valerius’ biosimilar products. Under the agreement, Catalent Biologics will…
Catalent Restructures Organization To Support Biologics Development
Catalent Pharma Solutions, a global provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer health products, announced key organizational changes within its biologics business to further align its organization with customer demand for integrated and comprehensive, end-to-end biologics solutions. The reorganization follows the company’s 2017 acquisition of Cook Pharmica LLC, and with…
Catalent Collaborates On Development Of Targeted Immuno-Oncology Therapy
Catalent Signs Commercial Manufacturing Agreement with US WorldMeds for Lofexidine
Pfizer Partners with Catalent for the Manufacture of Advil Liqui-Gels Minis
Following a successful 20-year collaboration on the development and manufacture of Advil® Liqui-Gels® (ibuprofen), Catalent Pharma Solutions has entered into an exclusive long-term supply agreement to produce the next generation of Pfizer Inc.’s leading over-the-counter (OTC) pain relief product with the launch of new Advil Liqui-Gels Minis, using Catalent’s innovative softgel platform OptiGel™ Mini technology.…